Recruiting studies: Ros1 Gene Rearrangement

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (A
Phase 1/Phase 2 · 63 location(s) · Nuvalent Inc. · NCT05118789 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116 Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Phase 1 · 1 location(s) · Guangzhou JOYO Pharma Co., Ltd · NCT06128148 Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
Phase 2 · 20 location(s) · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · NCT06552234 Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05681780 REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
Phase 2 · 16 location(s) · MedSIR · NCT06315010

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.